AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial
-
Published:2023-08
Issue:
Volume:62
Page:102106
-
ISSN:2589-5370
-
Container-title:eClinicalMedicine
-
language:en
-
Short-container-title:eClinicalMedicine
Author:
Zhao Yuanyuan, Chen Gang, Chen Jianhua, Zhuang Li, Du Yingying, Yu Qitao, Zhuang Wu, Zhao Yanqiu, Zhou Ming, Zhang Weidong, Zhang Yu, Wan Yixin, Li Wenting, Song Weifeng, Wang Zhongmin Maxwell, Li Baiyong, Xia Michelle, Yang Yunpeng, Fang Wenfeng, Huang Yan, Zhang LiORCID
Reference36 articles.
1. FDA approval summary: pembrolizumab, atezolizumab, and cemiplimab-rwlc as single agents for first-line treatment of advanced/metastatic PD-L1-high NSCLC;Akinboro;Clin Cancer Res,2022 2. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC;Herbst;N Engl J Med,2020 3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019 4. LBA52 EMPOWER-Lung 1: phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%;Sezer;Ann Oncol,2020 5. First-line immunotherapy for non-small-cell lung cancer;Reck;J Clin Oncol,2022
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|